Skip to main content
Equibles
ACET logo

ACET · Adicet Bio, Inc. · Metrics

Track ACET — free

Use ACET with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ACET.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.93 -0.06 (-2.01%) At close · Nov 12
Rebalance outlook locked
Going-concern doubt — flagged Nov 5, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on our recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, our outstanding and future payment obligations, and the potential need to raise additional capital to finance our future operations, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period at least twelve months from the date of issuance of these unaudited consolidated financial statements.”
View the 10-Q filed Nov 5, 2026
Market Cap
$27.43M
Shares
9.36M
Volume · Nov 12 371.41K Avg daily vol (3M) 226.86K

ACET metrics

56 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.93
Market cap
$27.43M

Price action

23 metrics
Price change (1W)
-3.5%
Price change (30D)
-41.5%
Price change (3M)
-63.8%
Price change (6M)
-62.9%
Price change (YTD)
-64.5%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
76.4%
Annualized volatility (3M)
86.9%
Implied volatility (30D)
157.7%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
2.1
RSI (14D)
19.4
Price vs SMA 50
-51.7%
Price vs SMA 200
-60.0%
Avg volume (3M)
221,754
Relative volume
1.9
Average dollar volume
$1.38M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
9.36M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.3
reciprocal yield 366.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-325.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-05

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$95.55M
Net income (TTM)
−$91.00M
Trailing 12 months
Diluted EPS (TTM)
$-7.42
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$10.97

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+88.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-88.6%
Return on assets
-70.6%
Debt / equity
0.0
Current ratio
6.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
6.1
Interest coverage
-1,038.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$26.30M
Latest balance sheet
Cash & equivalents
$27.11M
Total assets
$128.95M
Total debt
$806,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$80.14M
Capital expenditures (TTM)
$285,000
R&D (TTM)
$76.60M
SG&A (TTM)
—
Stock compensation (TTM)
$9.89M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
56
13F filer change QoQ
+7
Institutional ownership
65.8%
Conviction holders (share of 13F filers)
3.6%
Crowding (high-turnover and private-fund holders)
47.0%
Private-fund adviser ownership
45.2%
Active holders' share change QoQ
-5.6%
Holder tenure
10.1
Price vs estimated holder cost
-67.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.8%

Short interest

3 metrics
Short interest
4.9%
Latest settlement · 2.6 days to cover
Days to cover
2.6d
Short-squeeze score
44 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1720580 CUSIP 007002207 13F (30d) 37 filings 25 filers Visit website Investor relations